Repligen (NASDAQ:RGEN) Stock Price Expected to Rise, Canaccord Genuity Group Analyst Says

Repligen (NASDAQ:RGEN) had its target price upped by equities research analysts at Canaccord Genuity Group from $145.00 to $180.00 in a note issued to investors on Monday, MarketBeat reports. The firm presently has a “hold” rating on the biotechnology company’s stock. Canaccord Genuity Group’s price target points to a potential upside of 0.63% from the company’s current price.

RGEN has been the topic of several other reports. Evercore reiterated an “outperform” rating and set a $160.00 price target on shares of Repligen in a research report on Monday, July 6th. Wells Fargo & Company upped their price objective on Repligen from $180.00 to $185.00 and gave the company an “overweight” rating in a report on Thursday, July 30th. Citigroup upgraded Repligen to a “buy” rating in a report on Tuesday, July 7th. UBS Group reaffirmed a “buy” rating on shares of Repligen in a research note on Tuesday, September 29th. Finally, Benchmark raised Repligen from a “hold” rating to a “buy” rating and set a $185.00 target price on the stock in a report on Tuesday, July 7th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating and four have issued a Hold rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $175.71.

Repligen Trading Up 1.4%

Repligen stock opened at $178.88 on Monday. The firm has a 50 day simple moving average of $176.41 and a 200-day simple moving average of $146.59. The company has a debt-to-equity ratio of 0.26, a current ratio of 9.05 and a quick ratio of 7.64. The stock has a market capitalization of $10.10 billion, a PE ratio of 89.56, a price-to-earnings-growth ratio of 3.22 and a beta of 1.08. Repligen has a 12-month low of $100.99 and a 12-month high of $198.87.

Repligen (NASDAQ:RGEN) last posted its quarterly earnings data on Tuesday, July 28th. The biotechnology company reported $0.54 EPS for the quarter, beating analysts’ consensus estimates of $0.45 by $0.09. The business had revenue of $204.13 million for the quarter, compared to analyst estimates of $201.59 million. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The business’s revenue for the quarter was up 11.9% on a year-over-year basis. During the same quarter last year, the business earned $0.26 earnings per share. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. As a group, equities research analysts expect that Repligen will post 2.06 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. United Capital Financial Advisors LLC acquired a new stake in Repligen during the 2nd quarter valued at $380,756,000. Wasatch Advisors LP lifted its holdings in shares of Repligen by 27.9% in the second quarter. Wasatch Advisors LP now owns 1,590,251 shares of the biotechnology company’s stock valued at $216,974,000 after purchasing an additional 346,720 shares in the last quarter. Congress Asset Management Co. boosted its position in shares of Repligen by 0.9% in the third quarter. Congress Asset Management Co. now owns 1,020,907 shares of the biotechnology company’s stock worth $196,249,000 after buying an additional 8,681 shares during the period. ABS Investment Management LLC acquired a new stake in shares of Repligen in the second quarter worth $191,016,000. Finally, Maverick Capital Ltd. acquired a new stake in shares of Repligen in the first quarter worth $178,946,000. Institutional investors and hedge funds own 97.64% of the company’s stock.

Repligen Company Profile

Repligen Corporation (NASDAQ:RGEN) develops and manufactures bioprocessing technologies used in the production of biological medicines. Its products support key stages of biopharmaceutical manufacturing, including upstream processing, downstream purification, filtration, process monitoring and fluid management.

The company’s offerings include chromatography products, filtration systems, single-use technologies, process analytics equipment and critical biological materials such as recombinant proteins.